MedWatch

Rebien sees positive market development for obesity drugs

The Novo Nordisk management, headed by Lars Rebien Sørensen, talk about the initial experiences with obesity drugs in the US. Read Medwatch’s coverage of a press conference about topics ranging from obesity to shoe size and learn why Rebien would not recommend a stock split just yet

Foto: Niels Hougaard / Jyllands-Posten

The collective Danish business press was gathered in Bagsværd, after Novo Nordisk announced its latest financial statement and opened its doors for a press conference.

Top-executive Lars Rebien Sørensen sported a dark-grey suit, a light-blue tie and an excessively wide smile. He struggled to conceal his joy over having to present yet another financial statement brimming with impressive growth rates across the board. But he promised to refrain from repeating the cocky remarks from last year’s press conference.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier